サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：凝固分析装置の世界市場-2023年～2030年
市場調査レポート
商品コード
1345448

凝固分析装置の世界市場-2023年～2030年

Global Coagulation Analyzers Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
凝固分析装置の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

凝固分析装置の世界市場は、2022年に38億米ドルに達し、2023-2030年の予測期間中にCAGR 6.4%で成長し、2030年には61億米ドルに達すると予測されています。

凝固分析装置は、血液凝固能を評価・定量化する特殊な検査機器です。出血性疾患、血栓症、凝固因子欠乏症など、止血や凝固に関連するさまざまな病状の診断やモニタリングに不可欠です。凝固分析装置は、プロトロンビン時間（PT）、活性化部分トロンボプラスチン時間（aPTT）、国際標準比（INR）、フィブリノゲン値、Dダイマーアッセイなど、幅広い検査を実施できます。これらの検査は凝固因子、血小板機能、線溶に関する貴重な情報を提供します。

さらに、慢性血液疾患の有病率の増加と凝固分析装置の進歩が、予測期間中に市場を牽引すると予想される要因です。

ダイナミクス

進化する迅速なポイントオブケア凝固分析とVizient社の革新的な技術契約が市場成長を牽引すると期待される

2023年8月4日、医療技術のリーディングカンパニーであるHemoSonics社は、Vizient社からInnovative Technology契約を獲得し、大きなマイルストーンを達成しました。Vizientは米国内の急性期病院の広大なネットワークを代表する企業であり、米国内の医療施設の半数以上を占めているため、これは重要な成果です。ヘモソニックス社のQuantra Hemostasisシステムは、医療現場における凝固解析に革命をもたらす最先端の医療技術であり、この功績の礎となっています。

QuantraシステムにはQuantraヘモスタシスアナライザー、QPlusおよびQStatカートリッジが含まれ、全血凝固解析のための完全なソリューションを提供します。HemoSonics社のQuantra Hemostasisシステムは、医療技術の絶え間ない進歩を示す代表的な例です。迅速かつ包括的な凝固解析をポイントオブケアで直接提供することで、このシステムは診断能力を大幅に向上させるだけでなく、米国中の病院で患者ケアと転帰を向上させる可能性を秘めています。

Vizient社がこのシステムを評価したことは、凝固分析により効率的で効果的なアプローチを提供することで、医療業界に前向きな変化をもたらす能力を強調するものです。したがって、上記の要因から、予測期間中に市場は拡大すると予想されます。

慢性血液疾患の有病率の増加が市場成長を促進する見込み

世界保健機関（WHO）の報告書2023によると、貧血は公衆衛生上の重要な問題であり、主に幼児、妊娠中および産後の女性、月経のある思春期の少女や女性に影響を及ぼします。貧血の負担が最も大きいのは低・中所得国で、特に農村部や貧困家庭、正式な教育を受けていない人たちです。

統計によると、世界全体では、6～59カ月の児童の40％、妊婦の37％、15～49歳の女性の30％が貧血に罹患しています。2019年には、貧血が障害による健康寿命の損失5,000万年を引き起こし、食事性鉄欠乏症、鎌状赤血球症、マラリアが主な原因となっています。

さらに、世界中で15歳から49歳までの約5億人の女性と、6カ月から59カ月の2億6,900万人の児童が貧血の影響を受けていると推定されています。2019年には、15歳から49歳の女性全体の約30％に当たる5億3,900万人の非妊娠女性と、約37％に当たる3,200万人の妊婦が貧血の影響を受けています。

世界保健機関（WHO）によると、最も影響を受ける2つの地域、アフリカと東南アジアでは、アフリカでは1億600万人の女性と1億300万人の児童が、東南アジアでは2億4,400万人の女性と8,300万人の児童が貧血の影響を受けると推定されています。従って、上記の要因から、予測期間中、市場は牽引役となることが期待されます。

機器コストの高さが市場成長の妨げになる見込み

凝固分析装置は非常に高価であり、SYSMEX CA-560の平均価格は1993ドルです。この高コストは、クリニックや小規模検査室のような小規模医療施設にとって、経済的な大きな障害となる可能性があります。このような施設では、これらの分析装置を購入するために予算の大部分を確保するのに苦労し、その結果、利用が制限される可能性があります。

凝固分析装置には初期購入費用以外にも、定期的なメンテナンス、校正、試薬などの消耗品の使用が必要であり、これらは医療施設の予算を圧迫しかねないです。資金力の乏しい小規模施設では、継続的な資金負担を必要とする技術への投資に消極的な場合もあります。したがって、上記の要因により、市場は予測期間中に低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病性神経障害性疼痛の潜在的治療法
      • 慢性血液疾患の有病率の増加
    • 抑制要因
      • 装置の高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • 特許分析
  • ロシア・ウクライナ紛争分析
  • DMI見解

第6章 COVID-19分析

第7章 製品タイプ別

  • 分析装置
    • 臨床検査分析装置
    • ポイントオブケア分析装置
  • 消耗品
  • 試薬

第8章 検査タイプ別

  • プロトロンビン時間（PT）
  • 活性化部分トロンボプラスチン時間（aPTT）
  • Dダイマー検査
  • フィブリノゲン検査
  • その他

第9章 技術別

  • 光学技術
  • 機械技術
  • 電気化学技術

第10章 エンドユーザー別

  • 病院
  • 臨床検査室
  • 研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Roche Diagnostics
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Siemens Healthineers AG
  • Helena Laboratories Corporation
  • Meril Life Sciences Pvt. Ltd.
  • Trivitron Healthcare
  • Sysmex Asia Pacific Pte Ltd
  • A&T Corp
  • Genrui Biotech Inc.
  • ERBA Diagnostics, Inc.
  • Maccura Biotechnology Co. Ltd

第14章 付録

目次
Product Code: MD6792

Overview

Global Coagulation Analyzers Market reached US$ 3.8 billion in 2022 and is expected to reach US$ 6.1 billion by 2030, growing with a CAGR of 6.4% during the forecast period 2023-2030.

Coagulation analyzers are specialized laboratory instruments that evaluate and quantify the blood's clotting ability. They are essential in the diagnosis and monitoring of various medical conditions related to hemostasis and coagulation, such as bleeding disorders, thrombosis, and clotting factor deficiencies. Coagulation analyzers can perform a wide range of tests, including prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), fibrinogen levels, and D-dimer assays, among others. These tests provide valuable information about clotting factors, platelet function, and fibrinolysis.

Furthermore, the increasing prevalence of chronic blood disorders and advancement in coagulation analyzers are the factors expected to drive the market over the forecast period.

Dynamics

Advancing Rapid Point-of-Care Coagulation Analysis and Innovative Technology Contract from Vizient is Expected to Drive the Market Growth

On August 4, 2023, HemoSonics, a leading healthcare technology firm, achieved a major milestone by securing an Innovative Technology contract award from Vizient. This is a significant accomplishment since Vizient represents a vast network of acute care hospitals throughout the United States, accounting for more than half of all such healthcare facilities in the country. The Quantra Hemostasis System from HemoSonics is the cornerstone of this achievement, representing cutting-edge medical technology that promises to revolutionize coagulation analysis in healthcare settings.

The Quantra system includes the Quantra Hemostasis Analyzer, as well as the QPlus and QStat cartridges, providing a complete solution for whole-blood coagulation analysis, all delivered at the point of care and yielding results in less than 15 minutes. The Quantra Hemostasis System from HemoSonics is a prime example of the continuous advancement of medical technology. By providing fast and comprehensive coagulation analysis directly at the point of care, the system not only represents a significant improvement in diagnostic capabilities but also holds the potential to enhance patient care and outcomes in hospitals across the United States.

Vizient's recognition of the system highlights its ability to bring about positive changes in the healthcare industry by offering a more efficient and effective approach to coagulation analysis. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Increasing Prevalence of Chronic Blood Disorders is Expected to Drive Market Growth

According to the World Health Organization Report 2023, anemia is a significant public health issue that primarily affects young children, pregnant and postpartum women, and menstruating adolescent girls and women. The greatest burden of anemia is borne by low- and lower-middle-income countries, particularly those living in rural areas, impoverished households, and with no formal education.

Statistics indicate that globally, anemia affects 40% of all children aged 6-59 months, 37% of pregnant women, and 30% of women aged between 15 and 49 years. In 2019, anemia caused 50 million years of healthy life loss due to disability, with dietary iron deficiency, thalassemia sickle cell trait, and malaria being the leading causes.

Furthermore, it is estimated that around 500 million women between the ages of 15 and 49, as well as 269 million children aged between 6 and 59 months, are affected by anemia worldwide. In 2019, 539 million non-pregnant women, which is around 30% of all women aged between 15 and 49, and 32 million pregnant women, which is around 37%, were affected by anemia.

The two most affected regions, Africa and South-East Asia, have an estimated 106 million women and 103 million children affected by anemia in Africa, and 244 million women and 83 million children affected in South-East Asia, according to the World Health Organization. Hence, owing to the above factors, the market is expected to drive over the forecast period.

High Cost of Equipment is Expected to Hamper the Market Growth

Coagulation analyzers are quite expensive, with the SYSMEX CA-560 costing an average of $1993. This high cost can pose a significant financial obstacle for smaller healthcare facilities like clinics or smaller laboratories. These facilities may struggle to set aside a large portion of their budget to purchase these analyzers, which may limit their accessibility.

Apart from the initial purchase cost, coagulation analyzers also require regular maintenance, calibration, and the use of consumables such as reagents, which can add up and strain the budgets of healthcare facilities. Smaller facilities with limited financial resources may be reluctant to invest in technology that requires ongoing financial commitments. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

Segment Analysis

The global coagulation analyzers market is segmented based on product type, test type, technology, end-user and region.

The D-Dimer Testing from the Test Type Segment Accounted for Approximately 43.7% of the Coagulation Analyzers Market Share

D-dimer testing is an essential part of coagulation analysis that enables healthcare professionals to assess whether there is an abnormal blood clot formation in the body. D-dimer is a protein fragment produced when fibrin, another protein involved in blood clot formation, breaks down. Elevated levels of D-dimer in the blood can indicate the presence of an active blood clotting process, which makes it a valuable diagnostic tool in various medical situations.

For instance, when a blood clot travels to the lungs and blocks a pulmonary artery, it results in Pulmonary Embolism (PE). In this case, D-Dimer testing is frequently used alongside other diagnostic techniques, such as computed tomography pulmonary angiography (CTPA), to assess the possibility of PE. Increased D-Dimer levels may necessitate additional imaging to confirm the diagnosis.

Furthermore, the rising incidence of thrombotic disorders, the growing aging population, advancements in analytical technologies, and the development of point-of-care D-Dimer testing devices are the factors expected to drive the market segment over the forecast period. For instance, in October 2021, Trivitron Healthcare collaborated with Diagon Ltd to release a range of Coagulation Analyzer products, which includes systems for coagulation testing and D-Dimer testing capabilities.

The launch of these new products provides healthcare providers with a wider range of options, which could lead to an increase in the adoption of D-Dimer testing. This launch is a significant advancement in the field of coagulation analysis, especially for D-Dimer testing. The introduction of new and innovative products with improved accuracy and scalability is expected to drive the adoption of D-Dimer testing in clinical and patient management across various healthcare settings in India. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period

Geographical Penetration

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Prevalence of Chronic Blood Disorders, and the Launch of Coagulation Analyzers

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of chronic blood disorders, and the launch of coagulation analyzers.

For instance, Siemens Healthineers showcased their commitment as a trusted partner in hemostasis testing at the 31st Congress of the International Society on Thrombosis and Haemostasis in Montreal, Canada, from June 24 to 28, 2023. They invited attendees to join them at ISTH 2024 in Bangkok, Thailand, where they plan to showcase their coagulation testing portfolio for the first time in Asia.

During the event, Siemens Healthineers placed their focus on their Coagulation Analyzers, which cater to the needs of various laboratories. They highlighted technological advancements aimed at streamlining hemostasis testing processes as well as introducing the CN-3000 and CN-6000 Hemostasis Systems, stressing their connectivity options, compact size, intelligent software, and high throughput.

Siemens Healthineers also discussed their scalable coagulation analyzer portfolio, which includes the CN-3000 and CN-6000 Systems, the CS-2500 System (a mid-volume automated solution), and the CS-5100 System (a high-volume automated solution). The company emphasized the advantages of automation in coagulation testing and shared customer success stories from Finland and Switzerland where automation enhanced their testing processes.

Furthermore, during the presentation, Siemens Healthineers highlighted the importance of digitalization in hemostasis testing. They introduced their Atellica Diagnostics IT solutions, which can help laboratories improve efficiency and patient care. Additionally, they discussed the potential of AI in predicting coagulation disorders and provided a downloadable poster on this topic.

Siemens Healthineers also emphasized their commitment to providing coagulation assays that aid physicians in making accurate diagnostic and therapeutic decisions. This commitment is particularly important in cases of von Willebrand disease (VWD) with a focus on improving patient outcomes.

They showcased their CN-3000 and CN-6000 Hemostasis Systems, which are their smallest, fastest, smartest, and most flexible hemostasis analyzers yet. These analyzers have intelligent software and connectivity options, making them suitable for laboratories with different testing volumes and needs. Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the coagulation analyzers market include: Roche Diagnostics, Siemens Healthineers AG, Helena Laboratories Corporation, Meril Life Sciences Pvt. Ltd., Trivitron Healthcare, Sysmex Asia Pacific Pte Ltd, A&T Corp, Genrui Biotech Inc., ERBA Diagnostics, Inc., and Maccura Biotechnology Co. Ltd among others.

COVID-19 Impact Analysis

The coagulation analyzers market has positively impacted by the COVID-19 pandemic. These medical devices are crucial in assessing a person's blood clotting ability, which is necessary for diagnosing and managing various medical conditions, including bleeding disorders and thrombosis. Due to the pandemic, there was an increased demand for coagulation testing as COVID-19 patients were often found to have coagulation abnormalities, including a higher risk of blood clots. Healthcare facilities and hospitals require more coagulation analyzers to effectively monitor and manage these patients.

Moreover, due to the increasing demand and the need to reduce the burden on central laboratories, there has been a noticeable trend towards the use of point-of-care devices for coagulation testing. These portable analyzers have made bedside testing more convenient and faster, leading to quicker treatment decisions by healthcare providers. The pandemic has led to more research on coagulation abnormalities associated with COVID-19, resulting in the development of new assays and technologies that improve the accuracy and diagnostic capabilities of coagulation analyzers.

By Product Type

  • Analyzers
    • Clinical Laboratory Analyzers
    • Point of Care Analyzers
  • Consumables
  • Reagents

By Test Type

  • Prothrombin Time (PT)
  • Activated Partial Thromboplastin Time (aPTT)
  • D-Dimer Testing
  • Fibrinogen Testing
  • Others

By Technology

  • Optical Technology
  • Mechanical Technology
  • Electrochemical Technology

By End User

  • Hospitals
  • Clinical Laboratories
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On May 9, 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, launched its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal, May 8-11, 2022.
  • On February 9, 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of the company's long-standing global supply, distributorship, sales, and service agreement for a broad portfolio of hemostasis products including a multi-year extension. Additionally, the company agreement includes the future distribution of Sysmex's CN-Series automated blood coagulation analyzers, the CN-3000 and CN-6000, by Siemens Healthineers bringing the next generation of fully-automated solutions for mid-and high-volume coagulation testing to laboratories. The companies plan for Siemens Healthineers to start commercialization of the Sysmex CN Systems in various countries later this year.
  • On October 20, 2021, Trivitron Healthcare, a leading medical devices company announced the launch of a new line of Coagulation Analyzer products manufactured by Diagon Ltd. Trivitron in partnership with Diagon-Vanguard Diagnostics India announced the introduction of these products for the Indian Diagnostics Market following the signing of a collaboration agreement between the companies. This launch augurs well for the medical fraternity as it enhances the efficacies in clinical decision-making and broadens patient management. The new products include the COAG Line automated, semi-automated, and POC systems manufactured by Diagon Hungary for reducing bleeding risk in extensive surgeries and checking the efficacy of haemostatic therapies and anti-coagulant drugs.

Why Purchase the Report?

  • To visualize the global coagulation analyzers market segmentation based on product type, test type, technology, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of coagulation analyzers market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global coagulation analyzers market report would provide approximately 69 tables, 70 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Technology
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Potential Treatment for Diabetic Neuropathic Pain
      • 4.1.1.2. Increasing Prevalence of Chronic Blood Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Equipment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Patent Analysis
  • 5.7. Russian-Ukraine Conflict Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Analyzers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Clinical Laboratory Analyzers
    • 7.2.4. Point of Care Analyzers
  • 7.3. Consumables
  • 7.4. Reagents

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Prothrombin Time (PT)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Activated Partial Thromboplastin Time (aPTT)
  • 8.4. D-Dimer Testing
  • 8.5. Fibrinogen Testing
  • 8.6. Others

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Optical Technology*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Mechanical Technology
  • 9.4. Electrochemical Technology

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Clinical Laboratories
  • 10.4. Research Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Tye
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Roche Diagnostics*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Siemens Healthineers AG
  • 13.3. Helena Laboratories Corporation
  • 13.4. Meril Life Sciences Pvt. Ltd.
  • 13.5. Trivitron Healthcare
  • 13.6. Sysmex Asia Pacific Pte Ltd
  • 13.7. A&T Corp
  • 13.8. Genrui Biotech Inc.
  • 13.9. ERBA Diagnostics, Inc.
  • 13.10. Maccura Biotechnology Co. Ltd

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us